Treatment planning of carbon ion radiotherapy for prostate cancer based on cellular experiments with PC3 human prostate cancer cells

[Purpose] Treatment plans for carbon ion radiotherapy (CIRT) in Japan are designed to uniformly deliver the prescribed clinical dose based on the radiosensitivity of human salivary gland (HSG) cells to the planning target volume (PTV). However, sensitivity to carbon beams varies between cell lines, that is, it should be checked that the clinical dose distribution based on the cell radiosensitivity of the treatment site is uniform within the PTV.[Methods] We modeled the linear energy transfer (LET) dependence of the linear-quadratic (LQ) coefficients specific to prostate cancer, which accounts for the majority of CIRT. This was achieved by irradiating prostate cancer cells (PC3) with X-rays from a 4 MV-Linac and carbon beams with different LETs of 11.1-214.3 keV/mu m. By using the radiosensitivity of PC3 cells derived from cellular experiments, we reconstructed prostate-cancer -specific clinical dose distributions on patient computed tomography (CT).[Results] The LQ coefficient, alpha, of PC3 cells was larger than that of HSG cells at low (<50 keV/mu m) LET and smaller at high (>50 keV/mu m) LET, which was validated by cellular experiments performed on rectangular SOBPs. The reconstructed dose distribution on patient CT was sloped when 1 fraction incident from the one side of the patient was considered, but remained uniform from the sum of 12 fractions of the left-right opposing beams (as is used in clinical practice).[Conclusion] Our study reveals the inhomogeneity of clinical doses in single-field plans calculated using the PC3 radiosensitivity data. However, this inhomogeneity is compensated by using the combination of left-right opposing beams.

Automated summary

This study investigates the treatment plans in carbon ion radiotherapy (CIRT) and finds the variation of sensitivity to carbon beams between different cell lines. It is necessary to ensure the uniform clinical dose distribution within the planning target volume (PTV) based on the cell radiosensitivity of the treatment site.